A Randomised, Parallel-Group, Double-Blind, Placebo-Controlled Phase III Trial Assessing the Efficacy and Safety of ALK Grass Tablet in Subjects With Seasonal Grass Pollen Induced Rhiniconjunctivitis.

Trial Profile

A Randomised, Parallel-Group, Double-Blind, Placebo-Controlled Phase III Trial Assessing the Efficacy and Safety of ALK Grass Tablet in Subjects With Seasonal Grass Pollen Induced Rhiniconjunctivitis.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Feb 2015

At a glance

  • Drugs Timothy grass pollen allergen extract (Grastek) (Primary)
  • Indications Grass pollen hypersensitivity; Rhinoconjunctivitis; Seasonal allergic rhinitis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors ALK-Abello
  • Most Recent Events

    • 02 Mar 2012 Two-year follow-up results published in the March issue of the Journal of Allergy and Clinical Immunology, according to an ALK Abello media release.
    • 28 Jan 2012 Two-year follow-up results published in the Journal of Allergy and Clinical Immunology.
    • 29 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top